Vaxart Obtains $12,500,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=20a8cc1b-778d-4116-bea9-d7eb9dd2bfd9&Preview=1 - Date
3/4/2010 - Company Name
Vaxart - Mailing Address
600 Townsend St San Francisco, CA 94103 - Company Description
The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine. - Website
http://www.vaxart.com - Transaction Type
Venture Equity - Transaction Amount
$12,500,000 - Transaction Round
Series B - Proceeds Purposes
The funding will be used to advance the Company’s lead product, an oral vaccine for Avian influenza, through Phase I clinical trials. - M&A Terms
- Venture Investor
Care Capital - Venture Investor
Undisclosed
